Asterias Biotherapeutics Inc (NYSEAMERICAN:AST) was the target of a large decrease in short interest during the month of November. As of November 30th, there was short interest totalling 2,514,268 shares, a decrease of 2.6% from the November 15th total of 2,582,415 shares. Currently, 7.9% of the company’s stock are short sold. Based on an average trading volume of 89,717 shares, the short-interest ratio is currently 28.0 days.

Several brokerages recently weighed in on AST. ValuEngine upgraded Asterias Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, August 29th. Zacks Investment Research upgraded Asterias Biotherapeutics from a “hold” rating to a “buy” rating and set a $3.75 target price for the company in a research note on Tuesday, October 10th. Finally, HC Wainwright restated a “buy” rating and set a $12.00 target price on shares of Asterias Biotherapeutics in a research note on Monday, October 2nd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $9.19.

Shares of Asterias Biotherapeutics (NYSEAMERICAN AST) opened at $2.10 on Friday. Asterias Biotherapeutics has a 52 week low of $1.95 and a 52 week high of $5.00.

TRADEMARK VIOLATION NOTICE: This article was first reported by Daily Political and is the property of of Daily Political. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://www.dailypolitical.com/2017/12/17/asterias-biotherapeutics-inc-ast-short-interest-down-2-6-in-november.html.

Asterias Biotherapeutics Company Profile

Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.

Receive News & Ratings for Asterias Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.